Summary

The global Thyroid Cancer Testing market is projected to grow from US$ 1960 million in 2025 to US$ 3390 million by 2032, at a CAGR of 8.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
The gross profit margin of major companies in the industry was approximately 45%–65%.
Thyroid Cancer Testing includes diagnostic assays and laboratory methods used to identify, classify, and assess thyroid malignancies and suspicious thyroid nodules. Testing may include cytology-supported molecular assays, gene mutation panels, gene expression classifiers, protein biomarkers, immunoassays, and other molecular diagnostic techniques. These tests support diagnosis, risk stratification, treatment selection, and follow-up and are increasingly used alongside ultrasound, fine-needle aspiration, pathology, and other clinical evaluation methods.
The industrial chain of Thyroid Cancer Testing includes upstream antibodies, primers, probes, sequencing reagents, enzymes, biomarkers, diagnostic instruments, sample-preparation products, and software; midstream covers assay development, diagnostic kit production, laboratory testing, sequencing, molecular analysis, validation, data interpretation, and quality control; downstream applications mainly include hospitals, pathology laboratories, molecular diagnostic laboratories, cancer centers, endocrinology clinics, and research institutions.
Thyroid cancer testing includes diagnostic methods used to identify, characterize, and support clinical management of suspected thyroid malignancies, including cytology, laboratory testing, molecular diagnostics, and related testing technologies. Market demand is supported by increasing detection of thyroid nodules, wider use of imaging examinations, greater awareness of thyroid disease, and growing demand for more accurate differentiation between benign and malignant lesions. Technology development is increasingly focused on molecular biomarkers, mutation analysis, gene-expression profiling, and combined interpretation of multiple diagnostic indicators. Molecular testing is particularly valuable for indeterminate thyroid nodules where conventional cytology cannot provide a definitive diagnosis. Precision oncology and personalized treatment planning also increase demand for more detailed molecular characterization. However, advanced testing costs, differences in clinical guidelines, reimbursement limitations, variable access to molecular diagnostics, and concerns regarding overdiagnosis can constrain market expansion. Future development will emphasize diagnostic accuracy, risk stratification, minimally invasive testing, standardized molecular interpretation, and closer integration of laboratory, imaging, and clinical information.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Thyroid Cancer Testing market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Veracyte, Inc.
Sonic Healthcare USA, Inc. / ThyroSeq
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
QIAGEN N.V.
Abbott Laboratories
Siemens Healthineers AG
Beckman Coulter, Inc.
Fujirebio Holdings, Inc.
Sysmex Corporation
Asuragen, Inc. / Bio-Techne Corporation
Illumina, Inc.
Amoy Diagnostics Co., Ltd.
Burning Rock Biotech Limited
Berry Oncology Corporation
BGI Genomics Co., Ltd.
Sansure Biotech Inc.
Tellgen Corporation
Segment by Type
Cytology and Histopathology Testing
Molecular Genetic Testing
Protein Biomarker and Immunological Testing
Segment by Specimen Type
Fine-needle Aspiration Samples
Surgical Tissue Samples
Blood and Other Liquid Samples
Segment by Turnaround Time
Rapid Testing（≤24 Hours）
Standard Testing（＞24 Hours–7 Days）
Extended Testing（＞7 Days）
Segment by Application
Malignancy Diagnosis
Indeterminate Nodule Risk Stratification
Treatment Selection and Recurrence Monitoring
Other
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Thyroid Cancer Testing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Thyroid Cancer Testing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Thyroid Cancer Testing Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Cytology and Histopathology Testing
1.2.3 Molecular Genetic Testing
1.2.4 Protein Biomarker and Immunological Testing
1.3 Market Segmentation by Specimen Type
1.3.1 Global Thyroid Cancer Testing Market Size by Specimen Type, 2021 vs 2025 vs 2032
1.3.2 Fine-needle Aspiration Samples
1.3.3 Surgical Tissue Samples
1.3.4 Blood and Other Liquid Samples
1.4 Market Segmentation by Turnaround Time
1.4.1 Global Thyroid Cancer Testing Market Size by Turnaround Time, 2021 vs 2025 vs 2032
1.4.2 Rapid Testing（≤24 Hours）
1.4.3 Standard Testing（＞24 Hours–7 Days）
1.4.4 Extended Testing（＞7 Days）
1.5 Market Segmentation by Application
1.5.1 Global Thyroid Cancer Testing Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Malignancy Diagnosis
1.5.3 Indeterminate Nodule Risk Stratification
1.5.4 Treatment Selection and Recurrence Monitoring
1.5.5 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Thyroid Cancer Testing Revenue Estimates and Forecasts (2021-2032)
2.2 Global Thyroid Cancer Testing Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Thyroid Cancer Testing Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Thyroid Cancer Testing Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Cytology and Histopathology Testing: Market Share by Key Players
3.3.2 Molecular Genetic Testing: Market Share by Key Players
3.3.3 Protein Biomarker and Immunological Testing: Market Share by Key Players
3.4 Global Thyroid Cancer Testing Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Thyroid Cancer Testing Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Thyroid Cancer Testing Market by Specimen Type
4.2.1 Global Revenue by Specimen Type (2021-2032)
4.2.2 Global Revenue-Based Market Share by Specimen Type (2021-2032)
4.3 Global Thyroid Cancer Testing Market by Turnaround Time
4.3.1 Global Revenue by Turnaround Time (2021-2032)
4.3.2 Global Revenue-Based Market Share by Turnaround Time (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Thyroid Cancer Testing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Thyroid Cancer Testing Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Thyroid Cancer Testing Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Thyroid Cancer Testing Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Thyroid Cancer Testing Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Thyroid Cancer Testing Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Thyroid Cancer Testing Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Thyroid Cancer Testing Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Thyroid Cancer Testing Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Thyroid Cancer Testing Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Thyroid Cancer Testing Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Veracyte, Inc.
11.1.1 Veracyte, Inc. Corporation Information
11.1.2 Veracyte, Inc. Business Overview
11.1.3 Veracyte, Inc. Thyroid Cancer Testing Product Features and Attributes
11.1.4 Veracyte, Inc. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.1.5 Veracyte, Inc. Thyroid Cancer Testing Revenue by Product in 2025
11.1.6 Veracyte, Inc. Thyroid Cancer Testing Revenue by Application in 2025
11.1.7 Veracyte, Inc. Thyroid Cancer Testing Revenue by Geographic Area in 2025
11.1.8 Veracyte, Inc. Thyroid Cancer Testing SWOT Analysis
11.1.9 Veracyte, Inc. Recent Developments
11.2 Sonic Healthcare USA, Inc. / ThyroSeq
11.2.1 Sonic Healthcare USA, Inc. / ThyroSeq Corporation Information
11.2.2 Sonic Healthcare USA, Inc. / ThyroSeq Business Overview
11.2.3 Sonic Healthcare USA, Inc. / ThyroSeq Thyroid Cancer Testing Product Features and Attributes
11.2.4 Sonic Healthcare USA, Inc. / ThyroSeq Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.2.5 Sonic Healthcare USA, Inc. / ThyroSeq Thyroid Cancer Testing Revenue by Product in 2025
11.2.6 Sonic Healthcare USA, Inc. / ThyroSeq Thyroid Cancer Testing Revenue by Application in 2025
11.2.7 Sonic Healthcare USA, Inc. / ThyroSeq Thyroid Cancer Testing Revenue by Geographic Area in 2025
11.2.8 Sonic Healthcare USA, Inc. / ThyroSeq Thyroid Cancer Testing SWOT Analysis
11.2.9 Sonic Healthcare USA, Inc. / ThyroSeq Recent Developments
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.3.2 F. Hoffmann-La Roche Ltd. Business Overview
11.3.3 F. Hoffmann-La Roche Ltd. Thyroid Cancer Testing Product Features and Attributes
11.3.4 F. Hoffmann-La Roche Ltd. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.3.5 F. Hoffmann-La Roche Ltd. Thyroid Cancer Testing Revenue by Product in 2025
11.3.6 F. Hoffmann-La Roche Ltd. Thyroid Cancer Testing Revenue by Application in 2025
11.3.7 F. Hoffmann-La Roche Ltd. Thyroid Cancer Testing Revenue by Geographic Area in 2025
11.3.8 F. Hoffmann-La Roche Ltd. Thyroid Cancer Testing SWOT Analysis
11.3.9 F. Hoffmann-La Roche Ltd. Recent Developments
11.4 Thermo Fisher Scientific Inc.
11.4.1 Thermo Fisher Scientific Inc. Corporation Information
11.4.2 Thermo Fisher Scientific Inc. Business Overview
11.4.3 Thermo Fisher Scientific Inc. Thyroid Cancer Testing Product Features and Attributes
11.4.4 Thermo Fisher Scientific Inc. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.4.5 Thermo Fisher Scientific Inc. Thyroid Cancer Testing Revenue by Product in 2025
11.4.6 Thermo Fisher Scientific Inc. Thyroid Cancer Testing Revenue by Application in 2025
11.4.7 Thermo Fisher Scientific Inc. Thyroid Cancer Testing Revenue by Geographic Area in 2025
11.4.8 Thermo Fisher Scientific Inc. Thyroid Cancer Testing SWOT Analysis
11.4.9 Thermo Fisher Scientific Inc. Recent Developments
11.5 QIAGEN N.V.
11.5.1 QIAGEN N.V. Corporation Information
11.5.2 QIAGEN N.V. Business Overview
11.5.3 QIAGEN N.V. Thyroid Cancer Testing Product Features and Attributes
11.5.4 QIAGEN N.V. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.5.5 QIAGEN N.V. Thyroid Cancer Testing Revenue by Product in 2025
11.5.6 QIAGEN N.V. Thyroid Cancer Testing Revenue by Application in 2025
11.5.7 QIAGEN N.V. Thyroid Cancer Testing Revenue by Geographic Area in 2025
11.5.8 QIAGEN N.V. Thyroid Cancer Testing SWOT Analysis
11.5.9 QIAGEN N.V. Recent Developments
11.6 Abbott Laboratories
11.6.1 Abbott Laboratories Corporation Information
11.6.2 Abbott Laboratories Business Overview
11.6.3 Abbott Laboratories Thyroid Cancer Testing Product Features and Attributes
11.6.4 Abbott Laboratories Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.6.5 Abbott Laboratories Recent Developments
11.7 Siemens Healthineers AG
11.7.1 Siemens Healthineers AG Corporation Information
11.7.2 Siemens Healthineers AG Business Overview
11.7.3 Siemens Healthineers AG Thyroid Cancer Testing Product Features and Attributes
11.7.4 Siemens Healthineers AG Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.7.5 Siemens Healthineers AG Recent Developments
11.8 Beckman Coulter, Inc.
11.8.1 Beckman Coulter, Inc. Corporation Information
11.8.2 Beckman Coulter, Inc. Business Overview
11.8.3 Beckman Coulter, Inc. Thyroid Cancer Testing Product Features and Attributes
11.8.4 Beckman Coulter, Inc. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.8.5 Beckman Coulter, Inc. Recent Developments
11.9 Fujirebio Holdings, Inc.
11.9.1 Fujirebio Holdings, Inc. Corporation Information
11.9.2 Fujirebio Holdings, Inc. Business Overview
11.9.3 Fujirebio Holdings, Inc. Thyroid Cancer Testing Product Features and Attributes
11.9.4 Fujirebio Holdings, Inc. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.9.5 Fujirebio Holdings, Inc. Recent Developments
11.10 Sysmex Corporation
11.10.1 Sysmex Corporation Corporation Information
11.10.2 Sysmex Corporation Business Overview
11.10.3 Sysmex Corporation Thyroid Cancer Testing Product Features and Attributes
11.10.4 Sysmex Corporation Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Asuragen, Inc. / Bio-Techne Corporation
11.11.1 Asuragen, Inc. / Bio-Techne Corporation Corporation Information
11.11.2 Asuragen, Inc. / Bio-Techne Corporation Business Overview
11.11.3 Asuragen, Inc. / Bio-Techne Corporation Thyroid Cancer Testing Product Features and Attributes
11.11.4 Asuragen, Inc. / Bio-Techne Corporation Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.11.5 Asuragen, Inc. / Bio-Techne Corporation Recent Developments
11.12 Illumina, Inc.
11.12.1 Illumina, Inc. Corporation Information
11.12.2 Illumina, Inc. Business Overview
11.12.3 Illumina, Inc. Thyroid Cancer Testing Product Features and Attributes
11.12.4 Illumina, Inc. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.12.5 Illumina, Inc. Recent Developments
11.13 Amoy Diagnostics Co., Ltd.
11.13.1 Amoy Diagnostics Co., Ltd. Corporation Information
11.13.2 Amoy Diagnostics Co., Ltd. Business Overview
11.13.3 Amoy Diagnostics Co., Ltd. Thyroid Cancer Testing Product Features and Attributes
11.13.4 Amoy Diagnostics Co., Ltd. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.13.5 Amoy Diagnostics Co., Ltd. Recent Developments
11.14 Burning Rock Biotech Limited
11.14.1 Burning Rock Biotech Limited Corporation Information
11.14.2 Burning Rock Biotech Limited Business Overview
11.14.3 Burning Rock Biotech Limited Thyroid Cancer Testing Product Features and Attributes
11.14.4 Burning Rock Biotech Limited Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.14.5 Burning Rock Biotech Limited Recent Developments
11.15 Berry Oncology Corporation
11.15.1 Berry Oncology Corporation Corporation Information
11.15.2 Berry Oncology Corporation Business Overview
11.15.3 Berry Oncology Corporation Thyroid Cancer Testing Product Features and Attributes
11.15.4 Berry Oncology Corporation Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.15.5 Berry Oncology Corporation Recent Developments
11.16 BGI Genomics Co., Ltd.
11.16.1 BGI Genomics Co., Ltd. Corporation Information
11.16.2 BGI Genomics Co., Ltd. Business Overview
11.16.3 BGI Genomics Co., Ltd. Thyroid Cancer Testing Product Features and Attributes
11.16.4 BGI Genomics Co., Ltd. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.16.5 BGI Genomics Co., Ltd. Recent Developments
11.17 Sansure Biotech Inc.
11.17.1 Sansure Biotech Inc. Corporation Information
11.17.2 Sansure Biotech Inc. Business Overview
11.17.3 Sansure Biotech Inc. Thyroid Cancer Testing Product Features and Attributes
11.17.4 Sansure Biotech Inc. Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.17.5 Sansure Biotech Inc. Recent Developments
11.18 Tellgen Corporation
11.18.1 Tellgen Corporation Corporation Information
11.18.2 Tellgen Corporation Business Overview
11.18.3 Tellgen Corporation Thyroid Cancer Testing Product Features and Attributes
11.18.4 Tellgen Corporation Thyroid Cancer Testing Revenue and Gross Margin (2021-2026)
11.18.5 Tellgen Corporation Recent Developments

12 Thyroid Cancer Testing Value Chain and Ecosystem Analysis
12.1 Thyroid Cancer Testing Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Thyroid Cancer Testing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Thyroid Cancer Testing Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Thyroid Cancer Testing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Thyroid Cancer Testing Market Size Growth Rate by Specimen Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Thyroid Cancer Testing Market Size Growth Rate by Turnaround Time, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Thyroid Cancer Testing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Thyroid Cancer Testing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Thyroid Cancer Testing Revenue by Region (US$ Million), 2021-2026
Table 7. Global Thyroid Cancer Testing Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Thyroid Cancer Testing Revenue by Players (US$ Million), 2021-2026
Table 10. Global Thyroid Cancer Testing Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Thyroid Cancer Testing Revenue, 2025
Table 13. Global Thyroid Cancer Testing Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Thyroid Cancer Testing Companies Headquarters
Table 15. Global Thyroid Cancer Testing Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Thyroid Cancer Testing Revenue by Type (US$ Million), 2021-2026
Table 19. Global Thyroid Cancer Testing Revenue by Type (US$ Million), 2027-2032
Table 20. Global Thyroid Cancer Testing Revenue by Specimen Type (US$ Million), 2021-2026
Table 21. Global Thyroid Cancer Testing Revenue by Specimen Type (US$ Million), 2027-2032
Table 22. Global Thyroid Cancer Testing Revenue by Turnaround Time (US$ Million), 2021-2026
Table 23. Global Thyroid Cancer Testing Revenue by Turnaround Time (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Thyroid Cancer Testing Revenue by Application (US$ Million), 2021-2026
Table 26. Global Thyroid Cancer Testing Revenue by Application (US$ Million), 2027-2032
Table 27. Thyroid Cancer Testing High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Thyroid Cancer Testing Growth Accelerators and Market Barriers
Table 31. North America Thyroid Cancer Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Thyroid Cancer Testing Growth Accelerators and Market Barriers
Table 33. Europe Thyroid Cancer Testing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Thyroid Cancer Testing Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Thyroid Cancer Testing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Thyroid Cancer Testing Investment Opportunities and Key Challenges
Table 37. Central and South America Thyroid Cancer Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Thyroid Cancer Testing Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Thyroid Cancer Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Veracyte, Inc. Corporation Information
Table 41. Veracyte, Inc. Description and Major Businesses
Table 42. Veracyte, Inc. Product Features and Attributes
Table 43. Veracyte, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Veracyte, Inc. Revenue Proportion by Product in 2025
Table 45. Veracyte, Inc. Revenue Proportion by Application in 2025
Table 46. Veracyte, Inc. Revenue Proportion by Geographic Area in 2025
Table 47. Veracyte, Inc. Thyroid Cancer Testing SWOT Analysis
Table 48. Veracyte, Inc. Recent Developments
Table 49. Sonic Healthcare USA, Inc. / ThyroSeq Corporation Information
Table 50. Sonic Healthcare USA, Inc. / ThyroSeq Description and Major Businesses
Table 51. Sonic Healthcare USA, Inc. / ThyroSeq Product Features and Attributes
Table 52. Sonic Healthcare USA, Inc. / ThyroSeq Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Sonic Healthcare USA, Inc. / ThyroSeq Revenue Proportion by Product in 2025
Table 54. Sonic Healthcare USA, Inc. / ThyroSeq Revenue Proportion by Application in 2025
Table 55. Sonic Healthcare USA, Inc. / ThyroSeq Revenue Proportion by Geographic Area in 2025
Table 56. Sonic Healthcare USA, Inc. / ThyroSeq Thyroid Cancer Testing SWOT Analysis
Table 57. Sonic Healthcare USA, Inc. / ThyroSeq Recent Developments
Table 58. F. Hoffmann-La Roche Ltd. Corporation Information
Table 59. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 60. F. Hoffmann-La Roche Ltd. Product Features and Attributes
Table 61. F. Hoffmann-La Roche Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. F. Hoffmann-La Roche Ltd. Revenue Proportion by Product in 2025
Table 63. F. Hoffmann-La Roche Ltd. Revenue Proportion by Application in 2025
Table 64. F. Hoffmann-La Roche Ltd. Revenue Proportion by Geographic Area in 2025
Table 65. F. Hoffmann-La Roche Ltd. Thyroid Cancer Testing SWOT Analysis
Table 66. F. Hoffmann-La Roche Ltd. Recent Developments
Table 67. Thermo Fisher Scientific Inc. Corporation Information
Table 68. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 69. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 70. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Thermo Fisher Scientific Inc. Revenue Proportion by Product in 2025
Table 72. Thermo Fisher Scientific Inc. Revenue Proportion by Application in 2025
Table 73. Thermo Fisher Scientific Inc. Revenue Proportion by Geographic Area in 2025
Table 74. Thermo Fisher Scientific Inc. Thyroid Cancer Testing SWOT Analysis
Table 75. Thermo Fisher Scientific Inc. Recent Developments
Table 76. QIAGEN N.V. Corporation Information
Table 77. QIAGEN N.V. Description and Major Businesses
Table 78. QIAGEN N.V. Product Features and Attributes
Table 79. QIAGEN N.V. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. QIAGEN N.V. Revenue Proportion by Product in 2025
Table 81. QIAGEN N.V. Revenue Proportion by Application in 2025
Table 82. QIAGEN N.V. Revenue Proportion by Geographic Area in 2025
Table 83. QIAGEN N.V. Thyroid Cancer Testing SWOT Analysis
Table 84. QIAGEN N.V. Recent Developments
Table 85. Abbott Laboratories Corporation Information
Table 86. Abbott Laboratories Description and Major Businesses
Table 87. Abbott Laboratories Product Features and Attributes
Table 88. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Abbott Laboratories Recent Developments
Table 90. Siemens Healthineers AG Corporation Information
Table 91. Siemens Healthineers AG Description and Major Businesses
Table 92. Siemens Healthineers AG Product Features and Attributes
Table 93. Siemens Healthineers AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Siemens Healthineers AG Recent Developments
Table 95. Beckman Coulter, Inc. Corporation Information
Table 96. Beckman Coulter, Inc. Description and Major Businesses
Table 97. Beckman Coulter, Inc. Product Features and Attributes
Table 98. Beckman Coulter, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Beckman Coulter, Inc. Recent Developments
Table 100. Fujirebio Holdings, Inc. Corporation Information
Table 101. Fujirebio Holdings, Inc. Description and Major Businesses
Table 102. Fujirebio Holdings, Inc. Product Features and Attributes
Table 103. Fujirebio Holdings, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Fujirebio Holdings, Inc. Recent Developments
Table 105. Sysmex Corporation Corporation Information
Table 106. Sysmex Corporation Description and Major Businesses
Table 107. Sysmex Corporation Product Features and Attributes
Table 108. Sysmex Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Sysmex Corporation Recent Developments
Table 110. Asuragen, Inc. / Bio-Techne Corporation Corporation Information
Table 111. Asuragen, Inc. / Bio-Techne Corporation Description and Major Businesses
Table 112. Asuragen, Inc. / Bio-Techne Corporation Product Features and Attributes
Table 113. Asuragen, Inc. / Bio-Techne Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Asuragen, Inc. / Bio-Techne Corporation Recent Developments
Table 115. Illumina, Inc. Corporation Information
Table 116. Illumina, Inc. Description and Major Businesses
Table 117. Illumina, Inc. Product Features and Attributes
Table 118. Illumina, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Illumina, Inc. Recent Developments
Table 120. Amoy Diagnostics Co., Ltd. Corporation Information
Table 121. Amoy Diagnostics Co., Ltd. Description and Major Businesses
Table 122. Amoy Diagnostics Co., Ltd. Product Features and Attributes
Table 123. Amoy Diagnostics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Amoy Diagnostics Co., Ltd. Recent Developments
Table 125. Burning Rock Biotech Limited Corporation Information
Table 126. Burning Rock Biotech Limited Description and Major Businesses
Table 127. Burning Rock Biotech Limited Product Features and Attributes
Table 128. Burning Rock Biotech Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Burning Rock Biotech Limited Recent Developments
Table 130. Berry Oncology Corporation Corporation Information
Table 131. Berry Oncology Corporation Description and Major Businesses
Table 132. Berry Oncology Corporation Product Features and Attributes
Table 133. Berry Oncology Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Berry Oncology Corporation Recent Developments
Table 135. BGI Genomics Co., Ltd. Corporation Information
Table 136. BGI Genomics Co., Ltd. Description and Major Businesses
Table 137. BGI Genomics Co., Ltd. Product Features and Attributes
Table 138. BGI Genomics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. BGI Genomics Co., Ltd. Recent Developments
Table 140. Sansure Biotech Inc. Corporation Information
Table 141. Sansure Biotech Inc. Description and Major Businesses
Table 142. Sansure Biotech Inc. Product Features and Attributes
Table 143. Sansure Biotech Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Sansure Biotech Inc. Recent Developments
Table 145. Tellgen Corporation Corporation Information
Table 146. Tellgen Corporation Description and Major Businesses
Table 147. Tellgen Corporation Product Features and Attributes
Table 148. Tellgen Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Tellgen Corporation Recent Developments
Table 150. Technologies, Platforms and Infrastructure
Table 151. Distributors List
Table 152. Market Trends and Market Evolution
Table 153. Market Drivers and Opportunities
Table 154. Market Challenges, Risks, and Restraints
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Thyroid Cancer Testing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Cytology and Histopathology Testing Product Picture
Figure 3. Molecular Genetic Testing Product Picture
Figure 4. Protein Biomarker and Immunological Testing Product Picture
Figure 5. Global Thyroid Cancer Testing Market Size Growth Rate by Specimen Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Fine-needle Aspiration Samples Product Picture
Figure 7. Surgical Tissue Samples Product Picture
Figure 8. Blood and Other Liquid Samples Product Picture
Figure 9. Global Thyroid Cancer Testing Market Size Growth Rate by Turnaround Time, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Rapid Testing（≤24 Hours） Product Picture
Figure 11. Standard Testing（＞24 Hours–7 Days） Product Picture
Figure 12. Extended Testing（＞7 Days） Product Picture
Figure 13. Global Thyroid Cancer Testing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Malignancy Diagnosis
Figure 15. Indeterminate Nodule Risk Stratification
Figure 16. Treatment Selection and Recurrence Monitoring
Figure 17. Other
Figure 18. Thyroid Cancer Testing Report Years Considered
Figure 19. Global Thyroid Cancer Testing Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 21. Global Thyroid Cancer Testing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Thyroid Cancer Testing Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Thyroid Cancer Testing Revenue-Based Market Share Ranking (2025)
Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 25. Cytology and Histopathology Testing Revenue-Based Market Share by Player in 2025
Figure 26. Molecular Genetic Testing Revenue-Based Market Share by Player in 2025
Figure 27. Protein Biomarker and Immunological Testing Revenue-Based Market Share by Player in 2025
Figure 28. Global Thyroid Cancer Testing Revenue-Based Market Share by Type (2021-2032)
Figure 29. Global Thyroid Cancer Testing Revenue-Based Market Share by Specimen Type (2021-2032)
Figure 30. Global Thyroid Cancer Testing Revenue-Based Market Share by Turnaround Time (2021-2032)
Figure 31. Global Thyroid Cancer Testing Revenue-Based Market Share by Application (2021-2032)
Figure 32. North America Thyroid Cancer Testing Revenue YoY (US$ Million), 2021-2032
Figure 33. North America Top 5 Players Thyroid Cancer Testing Revenue (US$ Million) in 2025
Figure 34. North America Thyroid Cancer Testing Revenue (US$ Million) by Application (2021-2032)
Figure 35. US Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 36. Canada Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 37. Mexico Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 38. Europe Thyroid Cancer Testing Revenue YoY (US$ Million), 2021-2032
Figure 39. Europe Top 5 Players Thyroid Cancer Testing Revenue (US$ Million) in 2025
Figure 40. Europe Thyroid Cancer Testing Revenue (US$ Million) by Application (2021-2032)
Figure 41. Germany Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 42. France Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 43. U.K. Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 44. Italy Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 45. Russia Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 46. Asia-Pacific Thyroid Cancer Testing Revenue YoY (US$ Million), 2021-2032
Figure 47. Asia-Pacific Top 8 Players Thyroid Cancer Testing Revenue (US$ Million) in 2025
Figure 48. Asia-Pacific Thyroid Cancer Testing Revenue (US$ Million) by Application (2021-2032)
Figure 49. Indonesia Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 50. Japan Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 51. South Korea Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 52. Australia Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 53. India Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 54. Indonesia Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 55. Vietnam Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 56. Malaysia Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 57. Philippines Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 58. Singapore Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 59. Central and South America Thyroid Cancer Testing Revenue YoY (US$ Million), 2021-2032
Figure 60. Central and South America Top 5 Players Thyroid Cancer Testing Revenue (US$ Million) in 2025
Figure 61. Central and South America Thyroid Cancer Testing Revenue (US$ Million) by Application (2021-2032)
Figure 62. Brazil Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 63. Argentina Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 64. Middle East and Africa Thyroid Cancer Testing Revenue YoY (US$ Million), 2021-2032
Figure 65. Middle East and Africa Top 5 Players Thyroid Cancer Testing Revenue (US$ Million) in 2025
Figure 66. Middle East and Africa Thyroid Cancer Testing Revenue (US$ Million) by Application (2021-2032)
Figure 67. GCC Countries Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 68. Israel Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 69. Egypt Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 70. South Africa Thyroid Cancer Testing Revenue (US$ Million), 2021-2032
Figure 71. Thyroid Cancer Testing Value Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed